Aydanian A - Search Results

1

FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.

Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, Norsworthy KJ, Przepiorka D, Nie L, Liu J, Sheth CM, Shapiro M, Farrell AT, Pazdur R. Jen EY, et al. Among authors: aydanian a. Clin Cancer Res. 2018 Jul 15;24(14):3242-3246. doi: 10.1158/1078-0432.CCR-17-3179. Epub 2018 Feb 23. Clin Cancer Res. 2018. PMID: 29476018

2

Diversity of the antibody response to tetanus toxoid: comparison of hybridoma library to phage display library.

Sorouri M, Fitzsimmons SP, Aydanian AG, Bennett S, Shapiro MA. Sorouri M, et al. Among authors: aydanian ag. PLoS One. 2014 Sep 30;9(9):e106699. doi: 10.1371/journal.pone.0106699. eCollection 2014. PLoS One. 2014. PMID: 25268771 Free PMC article.

3

Multiple factors influence the contribution of individual immunoglobulin light chain genes to the naïve antibody repertoire.

Fitzsimmons SP, Aydanian AG, Clark KJ, Shapiro MA. Fitzsimmons SP, et al. Among authors: aydanian ag. BMC Immunol. 2014 Oct 30;15:51. doi: 10.1186/s12865-014-0051-2. BMC Immunol. 2014. PMID: 25359572 Free PMC article.

4

Genetic diversity of O-antigen biosynthesis regions in Vibrio cholerae.

Aydanian A, Tang L, Morris JG, Johnson JA, Stine OC. Aydanian A, et al. Appl Environ Microbiol. 2011 Apr;77(7):2247-53. doi: 10.1128/AEM.01663-10. Epub 2011 Feb 11. Appl Environ Microbiol. 2011. PMID: 21317260 Free PMC article.

5

Genetic relatedness of selected clinical and environmental non-O1/O139 Vibrio cholerae.

Aydanian A, Tang L, Chen Y, Morris JG Jr, Olsen P, Johnson JA, Nair GB, Stine OC. Aydanian A, et al. Int J Infect Dis. 2015 Aug;37:152-8. doi: 10.1016/j.ijid.2015.07.001. Epub 2015 Jul 8. Int J Infect Dis. 2015. PMID: 26164777 Free PMC article.

6

Molecular epidemiology of O139 Vibrio cholerae: mutation, lateral gene transfer, and founder flush.

Garg P, Aydanian A, Smith D, J Glenn M Jr, Nair GB, Stine OC. Garg P, et al. Among authors: aydanian a. Emerg Infect Dis. 2003 Jul;9(7):810-4. doi: 10.3201/eid0907.030038. Emerg Infect Dis. 2003. PMID: 12890320 Free PMC article.

7

Different mutations in the same codon of the proteolipid protein gene, PLP, may help in correlating genotype with phenotype in Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2).

Hodes ME, Zimmerman AW, Aydanian A, Naidu S, Miller NR, Garcia Oller JL, Barker B, Aleck KA, Hurley TD, Dlouhy SR. Hodes ME, et al. Among authors: aydanian a. Am J Med Genet. 1999 Jan 15;82(2):132-9. doi: 10.1002/(sici)1096-8628(19990115)82:2<132::aid-ajmg6>3.0.co;2-4. Am J Med Genet. 1999. PMID: 9934976

8

A de novo mutation (C755T; Ser252Phe) in exon 6 of the proteolipid protein gene responsible for Pelizaeus-Merzbacher disease.

Hodes ME, Aydanian A, Dlouhy SR, Whelan DT, Heshka T, Ronen G. Hodes ME, et al. Among authors: aydanian a. Clin Genet. 1998 Sep;54(3):248-9. doi: 10.1111/j.1399-0004.1998.tb04295.x. Clin Genet. 1998. PMID: 9788732 No abstract available.

9

X-linked spastic paraplegia due to a mutation (C506T; Ser169Phe) in exon 4 of the proteolipid protein gene (PLP).

Hodes ME, Hadjisavvas A, Butler IJ, Aydanian A, Dlouhy SR. Hodes ME, et al. Among authors: aydanian a. Am J Med Genet. 1998 Feb 17;75(5):516-7. doi: 10.1002/(sici)1096-8628(19980217)75:5<516::aid-ajmg11>3.0.co;2-n. Am J Med Genet. 1998. PMID: 9489796

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page